Prostate Cancer Metastatic
Conditions
Brief summary
Primary Objective: To evaluate the safety of cabazitaxel (Jevtana) in patients with metastatic hormone refractory prostate cancer Secondary Objectives: 1. To describe the use of cabazitaxel (Jevtana) in combination with oral prednisolone for the treatment of patients with metastatic Hormone Refractory Prostate Cancer 2. To describe patient profile in terms of demography, disease characteristics and prior treatment history 3. To describe efficacy outcomes: radiological response (if available) using Recist criteria V 1.1 and Prostate Specific Antigen (PSA) response
Detailed description
The study consists of: * a screening phase (maximum length of 7-day). * a treatment phase with 21-day study treatment cycles. Patients continue to receive treatment until disease progression , death, unacceptable toxicity, investigator's decision or withdrawal of consent. * a 30-day follow-up visit after the last dose of study medication.
Interventions
Pharmaceutical form:Solution Route of administration: Intravenous
DRUGPrednisone
Pharmaceutical form:Tablet Route of administration: Oral
DRUGPrednisolone
Pharmaceutical form:Tablet Route of administration: Oral
Sponsors
Sanofi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Metastatic hormone refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen * Disease Progression during or after docetaxel-containing regimen for mHRPC * Surgical or medical castration * Patient is ≥ 18 years and ≤ 75 years of age * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate bone marrow, liver, and renal function: Neutrophils\> 1500 /mm3; Hemoglobin \> 10 g/dL; Platelets \> 100 x109/L; Bilirubin \< Upper Normal Limit (ULN); Serum Glutamate Oxaloacetate Transaminase (Aspartate Aminotransferase)/SGOT (AST) \< 1.5xULN; Serum Glutamate Pyruvate Transaminase (Alanine Aminotransferase)/SGPT (ALT) \< 1.5xULN; Creatinine \< 1.5xULN. In case of creatinine \> 1.0 x ULN and \< or = 1.5 x ULN, calculated creatinine clearance according to CKD-EPI formula should be \> or = 60 ml/min. * Written informed consent must be obtained prior to any study related procedures
Exclusion criteria
* Prior radiotherapy to ≥ 40% of bone marrow * Previous treatment with cabazitaxel (Jevtana®) * Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment * Active grade ≥2 peripheral neuropathy * Active grade ≥2 stomatitis * Active infection requiring systemic antibiotic or anti-fungal medication * Active cancer (other than mHRPC) including prior malignancy from which the patient has been disease-free for ≤5 years * Known brain or leptomeningeal involvement * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * History of severe hypersensitivity reaction (≥grade 3) or intolerance to prednisone or prednisolone * Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus) * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a 2 weeks wash-out period is necessary for patients who are already on these treatments). Participation in any other clinical trial with any investigational drug * Patient with reproductive potential not implementing accepted and effective method of contraception The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with Related Serious Adverse Events | up to13 months |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of use of cabazitaxel in terms of treatment duration, number of cycles, dose modifications | up to 13 months |
| Radiological overall response (if radiological tumor assessment done) using Recist criteria | up to 13 months |
| Number of patients with at least 50% decrease in PSA | up to 13 months |
Countries
India
Outcome results
None listed